Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.
Capricor's Duchenne cell therapy faces July 29 FDA advisory vote after Phase 3 data integrity criticism; shares crashed two-thirds. Regulatory caution on gene therapy validation signals elevated biotech pipeline and M&A risk.
An article from
News roundup
Capricor shares lost much of their value ahead of a high-stakes meeting. Elsewhere, AstraZeneca disclosed more pipeline trouble and a thrice-rejected medicine finally nabbed an approval.
Published July 27, 2026
Getty Images
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July…
FDA staff say Capricor's deramiocel fails to show clear efficacy for Duchenne, tanking shares 65%+ ahead of this week's adcomm…
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
Martin Shkreli accuses Capricor Therapeutics of fraud and predicts legal action against its CEO and consultant over patient data.
On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling…
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy…
